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Abstract
Whereas the molecular events underlying acute myeloid leukemia (AML) are increasingly identiﬁed, dynamics of hematologic recovery
following induction chemotherapy remain mysterious. Platelet recovery may vary between incomplete and excess recovery among
patients achieving remission. We analyzed platelet recovery after the ﬁrst induction cycle in 291 consecutive AML patients. We
deﬁned excess platelet rebound (EPR) as platelet increase above 500G/L. We observed EPR in 120 (41.2%) patients. EPR+ patients
had lower platelets at diagnosis, higher marrow inﬁltration, more frequentlyNPM1mutations, and were associated with ELN favorable
risk. Absence of EPR correlated with complex karyotypes, ELN intermediate-I and adverse risk, and therapy-related AML. Overall
survival was better in EPR+ patients than EPR- (median 125 vs 41 months; p=0.04), as was disease-free survival. By multivariate
analysis, EPR+ was an independent parameter associated with favorable survival. Plasma thrombopoietin (TPO) levels at diagnosis
indicated EPR+ (p<0.0001), while GATA-1, GATA-2, and MPL mRNA expression did not differ between EPR+ and EPR- patients.
Finally, transcription factors blocking early megakaryopoiesis were upregulated in EPR- patients, while NFE2 involved in late
megakaryocyte differentiation was increased in EPR+ patients. Our work identiﬁes mechanisms involved in platelet recovery after
induction chemotherapy.
Introduction
Risk stratiﬁcation in acute myeloid leukemia (AML) patients
undergoing intensive chemotherapy is predominantly relying on
disease characteristics obtained pre-treatment.1–3 Among them,
current classiﬁcation systems acknowledge disease-speciﬁc mo-
lecular and cytogenetic abnormalities as the major determi-
nants.4–6 In contrast, clinical parameters at diagnosis of AML
such as the degree of blast inﬁltration in the bone marrow and
peripheral blood, presence and degree of cytopenias or
leukocytosis, chemical parameters such as LDH, presence of
extramedullary disease, or deregulated expression of cell surface
markers hardly affect therapeutic decisions nowadays if at all.2–7
Whereas combined molecular and cytogenetic parameters allow
risk stratiﬁcation in the routine and in the clinical trial setting,
they ultimately represent a wide range as far as the outcome of
individual patients is concerned. Clearly, additional parameters
are needed to improve outcome prediction in individual AML
patients.
Data gathered after the start of AML treatment can potentially
be equally useful as pre-treatment characteristics. For example,
Keating et al suggested that the number of courses needed to
achieve CR was inversely related to remission duration, and
achievement of early remission (after the ﬁrst induction cycle) is
increasingly recognized as an important favorable prognostic
determinant.8 Similarly, the depth of response to induction
treatment assessed by quantitative determination of molecular
and/or immunophenotypic leukemia-speciﬁc marker proﬁles is
also of important prognostic relevance.9–15 In addition, next
generation sequencing (NGS) has allowed for the identiﬁcation of
persisting molecular mutations in remission samples, with some
of them predicting higher risk of relapse.16 Other parameters
obtained during treatment with favorable impact on relapse risk
may include the decrease of the stem cell mobilization potential,
delayed hematologic recovery after consolidation treatment, and
low levels of transfusion-dependent iron load.17–19
In this study, we assessed whether inter-individually differing
kinetics of platelet recovery after induction chemotherapy may
also confer relevant prognostic information. Thrombocytopenia
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is a common ﬁnding at diagnosis of AML, with surprisingly poor
correlation to the degree of bone marrow inﬁltration.20–21
Consequently, it was suggested that thrombocytopenia at
diagnosis of AML depends on deregulated cytokine expression
in speciﬁc leukemia subtypes rather than on the degree of bone
marrow inﬁltration per se.20–21 Similarly, recovery of platelets
after the ﬁrst induction cycle varies widely among individual
patients even if morphologic remission is achieved. In particular,
excess platelet rebound (EPR) with values exceeding 500G/L can
be observed in some patients. However, this clinical observation
of EPR is poorly understood so far, and its prognostic relevance is
unknown. In this study, we investigated whether EPR is
associated with distinct subtypes of AML and whether it confers
speciﬁc prognostic information.
Patients and methods
Patients and samples
In this single-center retrospective analysis, we investigated
consecutive adult AML patients, who received intensive induc-
tion chemotherapy at the University Hospital of Berne,
Switzerland between 01/2000 and 12/2016. We included
untreated patients with de novo AML and secondary (therapy-
associated or evolving from previous hematologic conditions)
AML. We excluded patients receiving palliative treatment from
this analysis, as well as patients, who were refractory to the ﬁrst
induction cycle and underwent a premature start of the second
induction cycle, since platelet recovery could not be assessed in
these patients. Informed consent from all patients was obtained
according to the Declaration of Helsinki, and the study had
approval by a decision of the local ethics committee of Bern,
Switzerland (decision number #223/15). Molecular screening for
FLT3 (ITD and TKD), NPM1, and TP53 mutations, and
conventional cytogenetic analysis of at least 20 metaphases was
available in all patients. We collected peripheral blood plasma,
peripheral blood mononuclear cells (PBMCs) and bone marrow
mononuclear cells (BMMCs) at the time of diagnosis before
initiation of treatment.
Treatment
Patients were treated in or according to the SAKK/HOVON-42,
-43, -92, -102, -103, or -132 protocols. Brieﬂy, patients received
intravenously cytarabine 200mg/m2 on days 1 to 7 and
idarubicine 12mg/m2 days 1 to 3 in cycle 1; and cytarabine
1000mg/m2/q12h days 1 to 6 and amsacrine 120mg/m2 days 1
to 3 (until 12/2013; thereafter, daunorubicin 60mg/m2 days 1, 3,
5) were given in cycle 2. For consolidation, allogeneic
hematopoietic stem cell transplantation was offered to poor
risk patients (with a sibling or an unrelated matched donor) and
to intermediate risk patients (with a sibling donor). The
remaining patients in CR1 preferentially received busulfan /
cyclophosphamide high-dose chemotherapy with autologous
transplantation, or (in case of failed stem cell collection) a third
cycle of conventional chemotherapy with mitoxantrone and
etoposide.22
Deﬁnitions
The reference platelet count at our laboratory is 150 to 450G/L.
Patients were considered to have excess platelet rebound (EPR) in
this study when the number of platelets exceeded 500G/L after
the ﬁrst induction chemotherapy cycle, and intervals to EPR were
counted starting from the ﬁrst day of the ﬁrst induction therapy.
All patients had undergone a previous chemotherapy-related
phase of thrombocytopenia before eventual subsequent EPR.
EPRwas considered as a parameter independent from the platelet
level at diagnosis of the AML. We compared AML patients with
EPR (EPR+) to AML patients without EPR (EPR). Concurring
severe infection as a possible cause for increased platelets counts
at the respective time point was excluded in all patients, who
ﬁnally were considered for the analysis.
Risk assessment followed the European Leukemia Net (ELN)
classiﬁcation as published in 2010.3 We used response criteria
according to the International Working Group for diagnosis,
standardization of response criteria, treatment outcomes, and
reporting standards for therapeutic trials in AML.23 Bone
marrow examinations were performed at days 18 and 28 of
each induction cycle.
Progression free survival was calculated from the date of CR1
until disease progression, death or last follow-up, whichever
occurred ﬁrst. Non-relapsing alive patients were censored at the
last date of follow up. Overall survival was calculated from the
date of CR1 until death or last follow-up. Patients still alive or
lost to follow-up were censored at the last date they were known
to be alive.
Statistical analysis
We calculated curves depicting progression-free survival and
overall survival according to the Kaplan–Meier method. Survival
analyses were performed using the log-rank method. Hazard
ratios to evaluate the impact of baseline characteristics on clinical
outcome were calculated using the log-rank method. All reported
p values were from two-tailed Fisher’s or unpaired t tests, and a
value of p<0.05 was considered to be statistically signiﬁcant.
Comparison of survival was performed using the log-rank
method. The statistical analysis applied GraphPad Prism®
Version 6.0 (GraphPad Software, La Jolla, CA).
Gene expression analysis
RNA was extracted from AML cells and quantiﬁed using qPCR.
The RNA extraction kit was supplied by Macherey-Nagel,
Düren, Germany. Reverse transcription was done with MMLV-
RT (Promega, Madison, WI). Real-time PCR was performed on
the ABI7500 Real-Time PCR Instrument using FAST Start
Universal probe master mix (Roche, Switzerland). The following
gene speciﬁc probes were used (cat# 4331182, Thermo Fisher
Scientiﬁc, Waltham, MA): Hs00180489_m1 for MPL;
Hs00920556_m1 for MYB; Hs00232351_m1 for NFE2;
Hs00958846_m1 for NF1A; Hs01085823_m1 for GATA1;
Hs00231119_m1 for GATA2; Hs00358836_m1 for KLF4; and
Hs02758991_g1 for GAPDH. MPL, MYB, NFE2, NF1A,
GATA1, GATA2 and KLF4 Ct values were normalized with
GAPDH Ct values (ddCt relative quantitation). Assays were
performed in four physical replicates each. Statistical analysis
used GraphPad Prism software for column analysis applying
Mann-Whitney tests. Data in scatter plots include median values.
Enzyme-linked immunosorbent assay (ELISA)
Thrombopoietin (TPO) levels were quantiﬁed in peripheral
blood plasma at diagnosis using the human TPO ELISA kit
(EHTHPO, Thermo Fisher Scientiﬁc). MPL protein levels were
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quantiﬁed in whole cell extracts of peripheral blood or bone
marrow mononuclear cells obtained at ﬁrst diagnosis using the
human MPL ELISA kit (OKCD07412, Aviva Systems Biology,
San Diego, CA). Whole cell extracts were prepared by lysis in
RIPA buffer on ice for 60minutes and centrifugation for 5
minutes. Protein extracts were diluted in TBS (1:100), and protein
concentration was quantiﬁed by absorbance measurement A280
on NanoDrop 2000 spectrophotometer (Thermo Fisher Scientif-
ic). MPL protein concentration was normalized to total protein
concentration. Plasma proteins and cellular protein extracts were
assessed in three physical replicates each. Statistical analysis was
performed on GraphPad Prism software using Mann-Whitney
tests in column analysis. Data with scatter plots include median
values.
Results
We retrospectively studied a cohort of 291 consecutive patients
with newly diagnosed AML, who received intensive standard
induction chemotherapy at the University Hospital Berne,
Switzerland, between 01/2000 and 12/2016. We excluded
AML patients with palliative treatment and patients, who were
refractory to the ﬁrst induction cycle and underwent a premature
start of the second induction cycle. Patients were analyzed
according to their maximum platelet value observed during
hematologic recovery after induction cycle 1. We found that 120
patients (41.2%) had maximum platelet values exceeding 500G/
L at least once and thus fulﬁlled the criteria for EPR (EPR+), while
maximum platelet levels did not reach 500G/L in 171 patients
(58.8%; EPR). The clinical characteristics at initial diagnosis
of AML of EPR+ patients compared to EPR patients are
summarized in Table 1.
Dynamics of platelet recovery
Across all patients of our study cohort, platelet levels reached
their maximum value after a median of 32 days after the start of
the ﬁrst induction cycle. Individual values are depicted in
supplemental Figure 1, panel A, (Supplemental Digital Content,
http://links.lww.com/HS/A29). After the start of the second
induction cycle, the median duration until maximum platelet
levels was longer with 37 days (supplemental Fig. 1, panel B,
Supplemental Digital Content, http://links.lww.com/HS/A29).
The maximum platelet levels after the ﬁrst induction cycle ranged
between 17G/L and 1,416G/L, with a median of 433G/L
(Supplemental Fig. 1; panel C, Supplemental Digital Content,
http://links.lww.com/HS/A29). After the second treatment cycle,
the top platelet levels ranged between 19G/L and 1020G/Lwith a
median of 248G/L as shown in panel D in the supplemental
Figure 1 (Supplemental Digital Content, http://links.lww.com/
HS/A29). Thus, the maximum platelet levels were higher after the
ﬁrst induction course as compared to the second induction
course.
Correlation studies with other peripheral blood
values, laboratory parameters, and FAB subtypes
The degree of leukocytosis or anemia at initial presentation was
not associated with EPR after induction cycle 1, whereas the
degree of thrombocytopenia was inversely correlated with the
occurrence of EPR+. EPR+ patients were more likely to have mild
thrombocytopenia (<100G/L) or strong thrombocytopenia
(<20G/L) at diagnosis of AML. Age, gender, LDH or FAB
subtypes were not associated with developing EPR+. Remark-
ably, none of the 15 patients with therapy-related AML (p=
0.011) and only 9 of 31 patients (p=0.059) with secondary AML
evolving from previous MDS showed EPR after cycle 1.
Correlation with inﬂammation parameters
We tried to correlate the occurrence of EPR+with increased levels
of C-reactive protein (CRP). Patients were separated according to
a cut-off of 25mg/L for CRP (reference level in our laboratory
was<5mg/L). We selected the threshold of 25mg/L for CRP, as
this was the median CRP level observed in the total cohort at the
time of hematologic recovery after the ﬁrst induction cycle. In
fact, platelet levels and the frequency of EPR+ were not
signiﬁcantly different in patients with CRP level ≥25mg/L as
compared to patients with CRP level<25mg/L (data not shown).
Table 1
Patient characteristics at diagnosis of AML
Platelets
<500 G/L
Platelets
≥500 G/L P
N (%) 171 (100) 120 (100)
Gender, female, n (%) 80 (47) 62 (52) n.s.
Age at diagnosis, median, years 55 52 n.s.
Leukocytes >20 G/L, n (%) 57 (33) 35 (29) n.s.
Leukocytes >100 G/L, n (%) 13 (7) 5 (4) n.s.
Hemoglobin<80 g/L, n (%) 64 (37) 41 (34) n.s.
Platelets >20 G/L, n (%) 152 (89) 71 (59) 0.007
Platelets >100 G/L, n (%) 125 (73) 51 (42) 0.001
LDHa >480 IU/L, n (%) 110 (64) 72 (60) n.s.
Bone marrow inﬁltration, % 53 74 0.033
Peripheral blast inﬁltration, % 39 40 n.s.
FABb subtypes:
M0, n (%) 23 (13) 7 (6) n.s.
M1, n (%) 30 (18) 22 (18) n.s.
M2, n (%) 37 (22) 29 (24) n.s.
M3, n (%) 9 (5) 16 (13) n.s.
M4, n (%) 21 (12) 15 (12) n.s.
M5, n (%) 10 (6) 19 (16) n.s.
M6, n (%) 2 (1) 3 (3) n.s.
M7, n (%) 2 (1) 1 (1) n.s.
Secondary AML from MDS, n (%) 22 (13) 9 (7) n.s.
Therapy-related AML, n (%) 15 (9) 0 (0) 0.011
Molecular and cytogenetic subgroups:
t(8;21)/RUNX1-RUNX1T1, n (%) 6 (4) 11 (10) n.s.
inv(16)/CBFB-MYH11, n (%) 5 (3) 6 (5) n.s.
NPM1mut, n (%) 19 (10) 25 (21) 0.022
FLT3-ITD, n (%) 18 (10) 10 (8) n.s.
NPM1mut/FLT3-ITD, n (%) 9 (5) 8 (7) n.s.
CEBPAmut, n (%) 4 (2) 4 (3) n.s.
normal karyotypes 26 (18) 21 (17) n.s.
other cytogenetic/molecular subtypes 11 (7) 9 (8) n.s.
trisomies, n (%) 13 (8) 4 (3) n.s.
monosomy 7/del(7q), n (%) 9 (5) 1 (1) n.s.
complex abnormalitiesc, n (%) 31 (19) 1 (1) <0.0001
ELNd risk groups:
favorable, n (%) 22 (13) 77 (64) <0.0001
intermediate-I, n (%) 71 (42) 30 (25) 0.028
intermediate-II, n (%) 11 (6) 5 (4) n.s.
adverse, n (%) 67 (39) 8 (7) <0.0001
a LDH= lactate dehydrogenase.
b FAB= French-American-British classiﬁcation.
c deﬁned by ≥3 clonal cytogenetic abnormalities.
d ELN=European Leukemia Net.
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These data do not support an association between EPR+ and an
inﬂammatory state in our cohort.
Association of maximum platelet levels with
cytogenetic and molecular subgroups
Among the cytogenetic subgroups, patients with complex
karyotype abnormalities were strongly associated with failing
to have EPR, with only 1 EPR+ patient among 32 patients (p<
0.0001). Most likely, due to the small numbers, no differences
between EPR+ and EPR were observed for subgroups with
other cytogenetic aberrations (Table 1). The median maximum
platelet levels between cytogenetic subgroups ranged between
630G/L in patients with t(8;21)/RUNX1-RUNX1T1 and 140G/
L in patients with chromosome 7 alterations or with complex
karyotype abnormalities (p=0.0363 andp=0.0018, respectively).
Moreover, among AML subgroups deﬁned by molecular
abnormalities, we identiﬁed patients with NPM1 mutations (in
the absence of a FLT3 mutation) to be correlated with having
EPR+ after induction cycle 1. We identiﬁed no signiﬁcant
differences for the other molecular markers, again, probably due
to small patient numbers within these subgroups (Table 1). The
median values and the distribution of individual values for each
molecular subgroup are depicted in Figure 1. Across subgroups,
signiﬁcant differences were observed such as for patients with
NPM1mutation (with FLT3 wild-type), who had higher median
platelet values (575G/L) as compared to, for example, patients
with chromosome 7 alterations or complex karyotypes (p=
0.0371 and p=0.0002, respectively).
When applying the ELN risk classiﬁcation, patients in the
favorable risk category presented signiﬁcantly more often with
EPR+ after cycle 1 (p<0.0001), whereas patients with
intermediate-I (p=0.028) or adverse risk (p<0.0001) predomi-
nantly had no EPR. The median maximum platelet value after
induction cycle 1 was 563G/L in ELN favorable-risk patients as
compared to 366G/L in intermediate-I (p=0.001) or to 292G/L
in adverse risk patients (p<0.0001), whereas differences between
intermediate-I and adverse-risk patients were not signiﬁcant.
Median values and distribution of individual platelet values for
the ELN risk groups are depicted in Figure 1.
Figure 1. (A) Maximumplatelet levels are depicted as observed during hematologic recovery after induction chemotherapy cycle 1 for the four ELN
risk groups (following the 2010 publication). (B) Themaximum platelet levels are shown as observed during hematologic recovery after induction chemotherapy
cycle 1 for the various molecular and cytogenetic subgroups.
B.R. Schnell et al. Rebound Thrombocytosis in AML
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Clinical outcomes in correlation to the maximum
platelet levels
The median disease-free survival was signiﬁcantly lower with 38
months in the 171 patients without EPR as compared to not being
reached in the 120 EPR+ patients (p=0.0422; Fig. 2). Relapse in
EPR+ and EPR patients both occurred after a median of 13
months. Also, the median overall survival of EPR patients was
worse with 42 months compared to 125 months in EPR+ patients
(p=0.0497). Supplementary Figure 2 (Supplemental Digital
Content, http://links.lww.com/HS/A29) indicates that the surviv-
al rates showed no signiﬁcant differences when EPR and EPR+
patients were compared within the four ELN risk categories. This
may also be related to the limited sample sizes of the different
subgroups.
Furthermore, we excluded the possibility that survival differ-
ences are more pronounced when even more stringent criteria for
the deﬁnition of EPR+ were applied: using a deﬁnition of EPR
above vs below 700G/L, overall survival did not differ
signiﬁcantly between the 2 groups (Supplementary Fig. 3,
Supplemental Digital Content, http://links.lww.com/HS/A29).
Finally, in amultivariate analysis, EPR after induction cycle 1was
an independent prognostic factor associated with favorable
overall survival together with age below vs above 60 years at
diagnosis and favorable ELN risk group (vs intermediate-I/-II and
adverse risk). In contrast, gender as well as peripheral leukocytes
and platelet values at diagnosis of the AML had no independent
prognostic impact by multivariate analysis (Table 2).
Experimental studies investigating the
pathophysiologic background of the level of platelet
recovery
In order to elucidate the underlying mechanism for EPR, we
compared data acquired in the 50 AML patients with the highest
platelet values (range 700 to 1400G/L) to the 50 AML patients
with the lowest maximum platelet values (range 10 to 120G/L)
after the ﬁrst induction cycle (Table 3). We assessed thrombo-
poietin protein (TPO) levels in plasma and protein levels of the
thrombopoietin receptor MPL in mononuclear cell extracts
(Fig. 3A) both obtained at diagnosis before initiation of
treatment. A higher plasma TPO level at diagnosis was the most
signiﬁcant marker to indicate EPR (p<0.0001), while MPL
protein levels in the mononuclear cell extracts did not differ
between the two groups. We also analyzed mRNA expression of
the thrombopoietin receptor gene MPL in patient samples
collected at diagnosis, as well as mRNA expression of
transcription factors involved in thrombopoiesis including the
megakaryocyte inhibitor MYB and the thrombopoietic factors
GATA1 and NFE2. Myeloid transcription factors crucial for
monocyte differentiation including GATA2, KLF4, and NF1A
were similarly investigated.
Figure 2. (A) Kaplan-Meier curves are presented for disease-free survival comparing AML patients with excess platelet rebound above 500G/L
after induction cycle 1 (EPR+) compared to EPR patients. (B) Kaplan-Meier curves are depicted for overall survival comparing AML patients with EPR after
induction cycle 1 (EPR+) compared to EPR patients. (C) Kaplan-Meier curves are shown for overall survival comparing the four ELN risk groups of the study cohort.
(2019) 3:2 www.hemaspherejournal.com
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We observed signiﬁcant differences in NFE2 gene expression
between both groups. In contrast, we found no correlation of
EPR with expression levels of MPL, GATA1, and GATA2 in
mononuclear cells at diagnosis. There were negative correlations
of EPR with expression levels of MYB, KLF4, and NF1A genes,
with signiﬁcant differences of expression levels of all 3 markers
between both groups (Fig. 3B and Table 2). These observations
are summarized in a model as depicted in Figure 4.
Discussion
In this study, we investigated the dynamics of platelet recovery
after the ﬁrst standard chemotherapy induction cycle in 291
newly diagnosed AML patients treated at a single academic
center. We found that excess platelet rebound (EPR+) deﬁned as
exceeding 500G/L is a common event identiﬁed in 120 patients
(41.2%). EPR+ was predominantly observed in ELN favorable
risk AML, and it was associated with signiﬁcantly better overall
and disease-free survival as compared to patients with platelet
levels below the respective threshold. In addition, EPR+
represented an independent prognostic parameter for improved
survival by multivariate analysis. Interestingly, a threshold of
platelets of 500G/L or more was best suited to deﬁne patients
with more favorable outcome.
Remarkably, the observation of EPR after the ﬁrst induction
cycle appears to be a hallmark of favorable risk AML patients. In
particular, ELN favorable risk subgroups consistently had more
often EPR after cycle 1 compared to intermediate-I or adverse risk
subgroups. In particular, patients with t(15;17)/PML-RARA, inv
(16)/CBFB-MYH11, t(8;21)/RUNX1-RUNX1T1 or NPM1
mutations (with FLT3 wild type) achieved EPR in more than
50% of cases, whereas EPR was a very rare event in patients with
chromosome 7 alterations or complex abnormalities. Although
the reasons remain unclear, one may speculate that the more
rapid blast clearance in patients with favorable risk already after
the ﬁrst induction cycle allows a more pronounced platelet
recovery. Strikingly, EPR never occurred in patients with
therapy-related AML.
Aiming to unravel the underlying pathophysiologic mecha-
nisms, we performed measurements of some growth factors,
receptors, and transcription factors with known involvement in
megakaryo- and thrombopoiesis in the plasma and in mononu-
clear cells obtained at diagnosis before chemotherapy. First, a
higher plasma thrombopoietin (TPO) level at diagnosis was a
reliable marker to indicate the occurrence of EPR (p<0.0001)
after the ﬁrst induction cycle, whereas we observed no differences
inMPL protein levels in mononuclear cells. In addition, we found
a positive correlation of EPR with higher mRNA expression
levels of MPL, GATA1, GATA2, and NFE2 genes in
mononuclear cells at diagnosis, whereas expression levels of
MYB, KLF4, and NF1A genes were inversely correlated.
Thrombopoietin (TPO) is considered the master regulator of
megakaryopoiesis. TPO is predominantly exerting its down-
stream effects during megakaryopoiesis as well as its upstream
effects on hematopoietic stem cells through its receptor MPL.24–
29 TPO levels are largely regulated by MPL receptor-mediated
cytokine-scavenging, with platelets andmegakaryocytes acting as
the primary scavengers.30–31 Previous work has suggested that
AML cells can express MPL,32 and that TPO can promote
growth of leukemic cells in vivo.33 Leukemic cells expressing high
levels of MPL were shown to clear TPO, thereby leading to
insufﬁcient cytokine levels for non-leukemic hematopoiesis.20
Consequently, MPL expression was identiﬁed to act as a central
predictor of thrombocytopenia in AML patients at diagnosis.20
Interestingly, these studies suggested a lack of correlation
between bone marrow blast inﬁltration and cytopenias in
AML at diagnosis.
Table 3
Expression of genes involved in megakaryopoiesis in the patients with minimum vs maximum platelet recovery after the ﬁrst induction
cycle
Parameter Platelet rebound<120 G/L Platelet rebound ≥700 G/L Pc
Platelets after 1st cycle, G/L, median (range)a 48 (10–117) 827 (700–1415) <0.0001
TPO plasma level at diagnosis, pg/mLl 7 (1–49) 35 (3–450) <0.0001
MPL at diagnosis, ng/mg, median (range) 0.34 (0.1–1.8) 0.34 (0.1–1.8) 0.8
dCt MPLb, median 6.3 4.8 0.476
dCt MYB 0.8 2.2 0.008
dCt GATA1 7.6 4.9 0.255
dCt GATA2 3.4 2.7 0.311
dCt NFE2 2.5 0.9 0.029
dCt NF1A 7.8 11.4 0.034
dCt KLF4 7.8 9.6 0.026
a The 50 patients with the lowest maximum platelet recovery are compared with the 50 patients with the highest platelet recovery after induction cycle 1. The median values of the two groups are indicated together
with the range.
b Median dCt levels are indicated per group in mononuclear cells obtained at diagnosis before initiation of treatment; dCt=Ct (gene) - Ct (GAPDH).
c Signiﬁcance is indicated according to the Mann-Whitney test.
Table 2
Multivariate Cox proportional hazard model for overall survival
adjusting for risk factors
Covariate 95% Conﬁdence Interval p value
EPR+a 0.592–0.902 0.031
Age at diagnosisb 1.004–1.052 0.023
ELN classiﬁcationc 0.336–0.779 0.018
Platelets at diagnosisd 0.807–1.352 0.552
Gendere 0.616–1.918 0.773
Leukocytes at diagnosisf 0.825–1.029 0.097
a EPR= excess platelet rebound after induction cycle 1 above 500G/L (EPR+) vs below 500G/L
(EPR).
b Age at diagnosis below vs over 60 years.
c ELN=European LeukemiaNet classiﬁcation favorable-risk versus intermediate-I/II/adverse-risk.
d platelets at diagnosis above versus below 100G/L.
e female vs male.
f Peripheral leukocytes at diagnosis below vs above 20G/L.
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Figure 3. Samples at diagnosis of the 50 AML patients with maximum values (TOP50: 700–1,400G/L) of excess platelet rebound (EPR) were
compared to the 50 patients with the lowest maximum number of platelets (BOT50: 10–120G/L) after induction chemotherapy cycle 1. (A)
Thrombopoietin (TPO) was assessed in the plasma by ELISA, and MPL protein was determined using lysates from leukemic blasts. Peripheral blood from healthy
volunteers is shown as a control. (B) mRNA expression using lysates from leukemic blasts at diagnosis in the two patient subgroups are presented as dCt values.
The median dCt values are not signiﬁcantly different forMPL gene expression, but they differ signiﬁcantly for KLF4,MYB, NF1A and NFE2. There are no signiﬁcant
differences for GATA1 and GATA2 gene expression.
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Noteworthy, we observed that MPL protein expression in
mononuclear cells at diagnosis did not differ between patients
with or without EPR after induction cycle 1. In contrast, TPO
plasma levels at diagnosis were signiﬁcantly higher in EPR+
patients after ﬁrst induction compared to patients without EPR.
These data suggest that differing dynamics between TPO and
MPL are involved at diagnosis and during hematologic recovery
after induction chemotherapy. Whereas high MPL expression in
leukemic cells at diagnosis of AML can lead to MPL receptor-
mediated cytokine-scavenging of TPO and to pronounced
thrombocytopenia independent of the degree of bone marrow
inﬁltration, the occurrence of EPR after induction treatment
seems to be independent of MPL expression on leukemic cells at
diagnosis, but strongly associated with TPO plasma levels at
diagnosis. In addition, AML patients with EPR in our cohort had
higher degrees of bone marrow inﬁltration at diagnosis and lower
platelet counts at diagnosis. Thus, high TPO levels at diagnosis in
EPR+ patients (probably due to increased bone marrow
inﬁltration) appear to lead to increased stimulation of mega-
karyopoiesis thereby translating into EPR during hematologic
recovery after blast clearance in induction cycle 1.
In summary, our study demonstrates that the achievement of
excess platelet rebound of 500G/L or more following ﬁrst
induction chemotherapy is strongly associated with more
favorable survival outcomes and with some speciﬁc favorable
genetic subgroups of AML. In contrast, patients with ELN
intermediate or adverse risk typically failed to show EPR.
Interestingly, we could demonstrate that the achievement of EPR
after the ﬁrst induction chemotherapy was correlated with higher
plasma thrombopoietin (TPO) level at diagnosis, as well as with
upregulation of some speciﬁc transcription factors involved in
megakaryocyte differentiation such as NFE2. Future research
may aim at further clarifying the background of hematologic
recovery as thismay facilitate the clinical interpretation of the early
course of patients with AML during induction chemotherapy.
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